238 related articles for article (PubMed ID: 24073922)
21. Eosinophil chimerism in the differential diagnosis between DEK-NUP214-positive acute myeloid leukaemia relapse and chronic graft-versus-host disease.
e Moura de Souza CL; Bub CB; Torres MA; Velloso ED; Silveira PA; Correia RP; Bacal NS; Mangueira CL; Fernandes JF; Odone Filho V; Hamerschlak N; Campregher PV
J Clin Pathol; 2015 Nov; 68(11):950-2. PubMed ID: 26193901
[No Abstract] [Full Text] [Related]
22. NUP214-RAC1 and RAC1-COL12A1 Fusion in Complex Variant Translocations Involving Chromosomes 6, 7 and 9 in an Acute Myeloid Leukemia Case with DEK-NUP214.
Abe A; Yamamoto Y; Iba S; Okamoto A; Tokuda M; Inaguma Y; Yanada M; Morishima S; Kanie T; Tsuzuki M; Akatsuka Y; Mizuta S; Okamoto M; Kameyama T; Mayeda A; Emi N
Cytogenet Genome Res; 2015; 146(4):279-84. PubMed ID: 26517539
[TBL] [Abstract][Full Text] [Related]
23. [Clinical observation on 16 cases of DEK-NUP214 fusion gene positive acute myeloid leukemia treated with allogeneic hematopoietic stem cell transplantation].
Xia J; Zhao Y; Wu XJ; Qiu HY; Tang XW; Wang Y; Jin ZM; Miao M; Ma X; Wu DP; Chen SN; Chen F
Zhonghua Xue Ye Xue Za Zhi; 2023 Dec; 44(12):1041-1044. PubMed ID: 38503531
[No Abstract] [Full Text] [Related]
24. The impact of the chromatin binding DEK protein in hematopoiesis and acute myeloid leukemia.
Wilcher KE; Page ERH; Privette Vinnedge LM
Exp Hematol; 2023 Jul; 123():18-27. PubMed ID: 37172756
[TBL] [Abstract][Full Text] [Related]
25. The characteristics and prognostic significance of the SET-CAN/NUP214 fusion gene in hematological malignancies: A systematic review.
Wang J; Zhan QR; Lu XX; Zhang LJ; Wang XX; Zhang HY
Medicine (Baltimore); 2022 Jul; 101(30):e29294. PubMed ID: 35905214
[TBL] [Abstract][Full Text] [Related]
26. Overexpression of the human DEK oncogene reprograms cellular metabolism and promotes glycolysis.
Matrka MC; Watanabe M; Muraleedharan R; Lambert PF; Lane AN; Romick-Rosendale LE; Wells SI
PLoS One; 2017; 12(5):e0177952. PubMed ID: 28558019
[TBL] [Abstract][Full Text] [Related]
27. DEK-AFF2 fusion-associated papillary squamous cell carcinoma of the sinonasal tract: clinicopathologic characterization of seven cases with deceptively bland morphology.
Kuo YJ; Lewis JS; Zhai C; Chen YA; Chernock RD; Hsieh MS; Lan MY; Lee CK; Weinreb I; Hang JF
Mod Pathol; 2021 Oct; 34(10):1820-1830. PubMed ID: 34108636
[TBL] [Abstract][Full Text] [Related]
28.
Choi YJ; Min YK; Lee ST; Choi JR; Shin S
Ann Lab Med; 2024 Jul; 44(4):335-342. PubMed ID: 38145892
[TBL] [Abstract][Full Text] [Related]
29. Chromatin redistribution of the DEK oncoprotein represses hTERT transcription in leukemias.
Karam M; Thenoz M; Capraro V; Robin JP; Pinatel C; Lancon A; Galia P; Sibon D; Thomas X; Ducastelle-Lepretre S; Nicolini F; El-Hamri M; Chelghoun Y; Wattel E; Mortreux F
Neoplasia; 2014 Jan; 16(1):21-30. PubMed ID: 24563617
[TBL] [Abstract][Full Text] [Related]
30. NUP214 in Leukemia: It's More than Transport.
Mendes A; Fahrenkrog B
Cells; 2019 Jan; 8(1):. PubMed ID: 30669574
[TBL] [Abstract][Full Text] [Related]
31. DEK, an autoantigen involved in a chromosomal translocation in acute myelogenous leukemia, binds to the HIV-2 enhancer.
Fu GK; Grosveld G; Markovitz DM
Proc Natl Acad Sci U S A; 1997 Mar; 94(5):1811-5. PubMed ID: 9050861
[TBL] [Abstract][Full Text] [Related]
32. The DEK oncoprotein binds to highly and ubiquitously expressed genes with a dual role in their transcriptional regulation.
Sandén C; Järvstråt L; Lennartsson A; Brattås PL; Nilsson B; Gullberg U
Mol Cancer; 2014 Sep; 13():215. PubMed ID: 25216995
[TBL] [Abstract][Full Text] [Related]
33. Melanoma proliferation and chemoresistance controlled by the DEK oncogene.
Khodadoust MS; Verhaegen M; Kappes F; Riveiro-Falkenbach E; Cigudosa JC; Kim DS; Chinnaiyan AM; Markovitz DM; Soengas MS
Cancer Res; 2009 Aug; 69(16):6405-13. PubMed ID: 19679545
[TBL] [Abstract][Full Text] [Related]
34. Diagnosis of rare subtypes of acute myeloid leukaemia and related neoplasms.
George TI; Bajel A
Pathology; 2021 Apr; 53(3):312-327. PubMed ID: 33676766
[TBL] [Abstract][Full Text] [Related]
35. Leukemia-Associated Nup214 Fusion Proteins Disturb the XPO1-Mediated Nuclear-Cytoplasmic Transport Pathway and Thereby the NF-κB Signaling Pathway.
Saito S; Cigdem S; Okuwaki M; Nagata K
Mol Cell Biol; 2016 Jul; 36(13):1820-35. PubMed ID: 27114368
[TBL] [Abstract][Full Text] [Related]
36. The human DEK oncogene stimulates β-catenin signaling, invasion and mammosphere formation in breast cancer.
Privette Vinnedge LM; McClaine R; Wagh PK; Wikenheiser-Brokamp KA; Waltz SE; Wells SI
Oncogene; 2011 Jun; 30(24):2741-52. PubMed ID: 21317931
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of mTORC1 by RAD001 (everolimus) potentiates the effects of 1,25-dihydroxyvitamin D(3) to induce growth arrest and differentiation of AML cells in vitro and in vivo.
Yang J; Ikezoe T; Nishioka C; Ni L; Koeffler HP; Yokoyama A
Exp Hematol; 2010 Aug; 38(8):666-76. PubMed ID: 20382200
[TBL] [Abstract][Full Text] [Related]
38. The DEK oncogene activates VEGF expression and promotes tumor angiogenesis and growth in HIF-1α-dependent and -independent manners.
Zhang Y; Liu J; Wang S; Luo X; Li Y; Lv Z; Zhu J; Lin J; Ding L; Ye Q
Oncotarget; 2016 Apr; 7(17):23740-56. PubMed ID: 26988756
[TBL] [Abstract][Full Text] [Related]
39. Synergistic Effects between mTOR Complex 1/2 and Glycolysis Inhibitors in Non-Small-Cell Lung Carcinoma Cells.
Jiang S; Zou Z; Nie P; Wen R; Xiao Y; Tang J
PLoS One; 2015; 10(7):e0132880. PubMed ID: 26176608
[TBL] [Abstract][Full Text] [Related]
40. MicroRNA-138 promotes neuroblastoma SH-SY5Y cell apoptosis by directly targeting DEK in Alzheimer's disease cell model.
Miao J; Jing J; Shao Y; Sun H
BMC Neurosci; 2020 Jul; 21(1):33. PubMed ID: 32736520
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
